Ten years of serological surveillance in England and Wales: Methods, results, implications and action

International Journal of Epidemiology

Volumn 29, Issue 2, 2000, Pages 362-368

  Osbome, Kate ^a   Gay, Nigel ^a   Hesketh, Louise ^b   Morgan Capner, Peter ^a   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

Immunization; Mathematical modelling; MMR; Serological surveillance; Vaccine preventable diseases

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; DATA BASE; FEMALE; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; NEWBORN; POPULATION RESEARCH; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RUBELLA; SERODIAGNOSIS; SEROEPIDEMIOLOGY; SEX DIFFERENCE; UNITED KINGDOM; VACCINATION;

EID: 0342749461     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/29.2.362     Document Type: Article

References (33)

1. Paul JR. Knowledge and Trends in Poliomyelitis: A Summary. Poliomyelitis: papers and discussions presented at the Second International Poliomyelitis Conference. JB Lippencott; Philadelphia, 1951.
2. Gear JHS. Distribution of Antibodies to Poliomyelitis Virus in the General Population. Poliomyelitis: papers and discussions presented at the Third International Poliomyelitis Conference. JB Lippencott; Philadelphia, 1954.
3. Cockburn WC. World aspects of the epidemiology of rubella. Am J Dis Child 1969:118:112-22.
4. Szmuness W, Dienstag JL, Purcell RH et al. The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol 1977:106:392-98.
5. Dienstag JL, Szmuness W, Stevens CE, Purcell RH. Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis 1978:137:328-40.
6. Frosner GG, Papaevangelou GJ, Butler R et al. Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. Am J Epidemiol 1979; 110:6 3-69.
7. Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg Camb 1985;94:365-435.
8. Anderson RM, Grenfell BT. Quantitative investigations of different rubella vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom. J Hyg Camb 1986:96:305-33.
9. Ukkonen P. Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979-1992. Scand J Infect Dis 1996; 28:31-35.
10. Chen HJ, Chang MH, Ni YH et al. Seroepidemiology of hepatitis B infection in children: ten years of mass vaccination in Taiwan. JAMA 1996:276:906-08.
11. Morgan-Capner P, Wright J, Miller CL, Miller E. Surveillance of antibody to measles, mumps and rubella by age. Br Med J 1988; 297:770-72.
12. Hesketh LM, Charlett A, Farrington CP, Miller E, Forsey T, Morgan-Capner P. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. J Virol Meth 1997;66:51-59.
13. Ramsay ME, Gay NJ, Miller E et al. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep 1994;4:R141-46.
14. Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol Infect 1995;115: 139-56.
15. Gay NJ, Ramsay ME, Cohen BJ et al. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun Dis Rep 1997;7:R17-21.
16. Hesketh LM, Rowlatt JD, Gay NJ, Morgan-Capner P, Miller E. Childhood infection with hepatitis A and B viruses in England and Wales. Commun Dis Rep 1997;7:R60-63.
17. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E. The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 1999;122:133-38.
18. Farrington CP. Modelling forces of infection for measles, mumps and rubella. Stat Med 1990:9:953-67.
19. Gay NJ, Hesketh LM, Cohen BJ et al. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Commun Dis Rep 1994;4:R104-07.
20. Osborne KP, Weinberg J, Miller E. The European Sero-Epidemiology Network. Eurosurveillance 1997;2:29-31.
21. Gay NJ, Miller E, Hesketh LM et al. Mumps surveillance in England and Wales supports the introduction of two dose vaccination schedule. Commun Dis Rep 1997;7:R21-26.
22. Miller E, Waight PA, Gay NJ et al. The epidemiology of rubella in England and Wales before and after the 1994 measles-rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep 1997;7:R26-32.
23. Esveld M. Serological surveillance in the Netherlands. Commun Dis Rep 1994;4:107-08.
24. Fleming DT, McQuillan GM, Johnson RE et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337: 1105-11.
25. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. 2nd Edn. Oxford: Oxford University Press, 1991.
26. CDSC. A second dose of MMR vaccine for children in the United Kingdom. Commun Dis Rep 1996;6:259.
27. Miller E, Rush M, Morgan-Capner P, Hutchinson D, Hindle L. Immunity to diphtheria in adults in England. Br Med J 1994:308:598.
28. Chief Medical Officer. Immunisation update. CMO'S Update 1994:2:1-2.
29. Fairley CK, Miller E. Varicella-zoster virus epidemiology - a changing scene. J Infect Dis 1996;174:S314-19.
30. Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E. Age-specific antibody prevalence to hepatitis A: implications for disease control. Epidemiol Infect 1994;113:113-20.
31. Ramsay M, Gay N, Balogun MA, Collins M. Control of hepatitis B in the UK. Vaccine 1998;16:S52-55.
32. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105:174-78.
33. Gray JJ, Jiang P, Morgan-Capner P, Desselburger U, Estes K. Prevalence of antibodies to Norwalk virus in England: detection by ELISA using baculovirus-expressed Norwalk virus capsid antigen. J Clin Microbiol 1993:31:1022-25.